RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Douglas M. Watts to Vaccines, Attenuated

This is a "connection" page, showing publications Douglas M. Watts has written about Vaccines, Attenuated.
Connection Strength

0.429
  1. Watts DM, Westover JLB, Palermo PM, Bailey KW, Morrill JC, Bettinger GE, Monath TP, Smith DR, Peters CJ, Pittman PR, Orbegozo J, Gowen BB. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
    View in: PubMed
    Score: 0.211
  2. Nyundo S, Adamson E, Rowland J, Palermo PM, Matiko M, Bettinger GE, Wambura P, Morrill JC, Watts DM. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12?NSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania. Onderstepoort J Vet Res. 2019 Jan 31; 86(1):e1-e8.
    View in: PubMed
    Score: 0.164
  3. Bamouh Z, Hamdi J, Elkarhat Z, Fellahi S, Omari Tadlaoui K, Watts DM, Fassi Fihri O, Elharrak M. Attenuation and genetic characteristics of a Moroccan strain of Camel pox virus. Vaccine. 2022 10 26; 40(45):6471-6480.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support